Subject category:
Entrepreneurship
Published by:
International Institute for Management Development (IMD)
Version: 26.01.2022
Revision date: 11-Feb-2022
Length: 17 pages
Data source: Field research
Share a link:
https://casecent.re/p/182037
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This is part of a case series. The A case tells the story of Anthony Giovinazzo's entrepreneurial journey with Cyna Pharma, which he built from the ground up. Cyna Pharma was a Canada-based specialty pharmaceutical company that was at the point of conducting Phase 3 clinical trials in 2016 for its main product: APL-130277 - a novel delivery mechanism for an existing drug called apomorphine, used for on-demand treatment of the debilitating off-episodes (freezing) associated with Parkinson's disease (PD). The case provides an overview of Anthony's unique background, the off-episodes associated with Parkinson's disease, the specialty biopharma sector, the funding rounds to get to Phase 3 clinical trials and the brushes with disaster along the way. It also describes the steps to getting listed on the NASDAQ and the benefits of doing so. After an earlier offer to acquire the company the case ends with a similar offer from Sundown Pharma a year later. As the case comes to a close, Anthony is faced with a moment of truth: Should he move forward with launching the product himself, or should he license his product with a partner or agree to an outright acquisition by a big pharma company?
Time period
The events covered by this case took place in 2002-2016.Geographical setting
Country:
Canada
Featured company
Cyna Pharma (Disguised)
Turnover:
USD 624 million
Industry:
Biopharmaceuticals
About
Abstract
This is part of a case series. The A case tells the story of Anthony Giovinazzo's entrepreneurial journey with Cyna Pharma, which he built from the ground up. Cyna Pharma was a Canada-based specialty pharmaceutical company that was at the point of conducting Phase 3 clinical trials in 2016 for its main product: APL-130277 - a novel delivery mechanism for an existing drug called apomorphine, used for on-demand treatment of the debilitating off-episodes (freezing) associated with Parkinson's disease (PD). The case provides an overview of Anthony's unique background, the off-episodes associated with Parkinson's disease, the specialty biopharma sector, the funding rounds to get to Phase 3 clinical trials and the brushes with disaster along the way. It also describes the steps to getting listed on the NASDAQ and the benefits of doing so. After an earlier offer to acquire the company the case ends with a similar offer from Sundown Pharma a year later. As the case comes to a close, Anthony is faced with a moment of truth: Should he move forward with launching the product himself, or should he license his product with a partner or agree to an outright acquisition by a big pharma company?
Settings
Time period
The events covered by this case took place in 2002-2016.Geographical setting
Country:
Canada
Featured company
Cyna Pharma (Disguised)
Turnover:
USD 624 million
Industry:
Biopharmaceuticals